

Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Perampanel (Fycompa®)		
Indication under review	Epilepsy		
Policy No:	APC 106		
Date of Issue/Date of re-issue:	March 2013, May 2015		
Review Date:	May 2018		
Policy Statement:			
Perampanel (Fycompa®) is indicated for use as an option for adjunctive treatment of patients with partial-onset epilepsy who have failed to achieve control after trying a minimum of 4 anticonvulsants. Initiation by secondary care specialists only.			
Traffic Light Status	Amber		
Key Points considered:			
<ul style="list-style-type: none"> • Must be initiated by Specialist or on the advice of a specialist. • Shared care should be agreed if prescribing is to be transferred to primary care 			
References:			
<ol style="list-style-type: none"> 1. Eisai Ltd. Perampanel (Fycompa®) tablets. Summary of product characteristics: www.medicines.org.uk Last updated: 30/08/2012 2. SMC http://www.scottishmedicines.org.uk/SMC_Advice/Advice/819_12_perampanel Fycompa/perampanel_Fycompa 3. Erhorn S. North East Treatment Advisory Group Perampanel for epilepsy. 			
Date taken to APC	March 2015		
Expired policy reviewed by APC:	6 th May 2015		
Date Ratified by GP MOC:	17 th June 2015		

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only